论文部分内容阅读
目的 :探讨血清 CK- MB检测在癌性心包积液治疗中的临床价值。方法 :以免疫抑制法测定血清 CK- MB 5次 :入院、出院及出院后 3月内每月 1次。观察组包括 5 4例癌性心包积液 ,对照组为 5 4例不伴心包积液的癌症患者。结果 :观察组血清 CK- MB的阳性率高于对照组 ,分别为 79.6 % (4 3/ 5 4 )和35 .18% (19/ 5 4 ) ,且在观察组中的降低和 /或升高与疗效相关 ,且差异有显著性 ;而对照组差异无显著性。结论 :血清 CK- MB含量与癌细胞浸润心包有关 ,其对癌性心包积液患者的病情、疗效、复发及预后评估有一定的参考价值。
Objective: To investigate the clinical value of serum CK-MB in the treatment of malignant pericardial effusion. Methods: Serum CK-MB was determined by immunosuppression 5 times: admission, discharge and discharge once a month within three months after discharge. The observation group included 54 cases of cancerous pericardial effusion and the control group of 54 patients with cancer without pericardial effusion. Results: The positive rate of serum CK-MB in the observation group was 79.6% (34/54) and 35.18% (19/54) respectively, and the decrease and / or increase in the observation group High and efficacy-related, and the difference was significant; while the control group no significant difference. CONCLUSION: Serum CK-MB level is related to infiltrating pericardium in cancer cells, which may be of reference value for the patients with malignant pericardial effusion and their prognosis.